Proscia has introduced the Fifth Generation of its Concentriq platform, helping pathologists focus on high-judgment decisions and enabling scientists to quickly move from early signals to evidence-based decisions.
The latest update introduces intelligence that draws on clinical and scientific context to support experts throughout drug discovery, development, and case review. Making this intelligence native to Concentriq required a new architecture. Designed alongside pathologists and scientists, Fifth Generation is the most significant advancement to Concentriq in five years. It brings domain-specific frontier vision, language, and multimodal models to the core of a technology stack built for enterprise-scale security, governance, and reliability.
This architecture enables the platform to unify images, metadata, and the context surrounding a case or study - from slide-level morphology and patient history to laboratory-specific protocols and translational data - giving experts and models the same complete picture. Intelligence draws on this picture to orchestrate the burdensome work surrounding case review and accelerate the discovery and development of advanced biomarkers. Outputs are transparent, reproducible, and interpretable for expert verification.
"AI is advancing rapidly," said Coleman Stavish, Chief Technology Officer of Proscia. "We took a first-principles approach, working backwards from how pathologists and scientists operate. Years of learning from our customers has helped us understand where complexity slows them down and where judgment gets crowded out by process. Fifth Generation is designed to reduce that burden so experts can focus on the decisions that matter most."
- Accelerate case review. Concentriq brings the flow state of the microscope to an enterprise-scale digital platform, combining the microscope’s tactile nature with an understanding of the case and context. Intelligent navigation helps pathologists move quickly through tissue while skin slides orient automatically to preserve the mental model needed to assess findings such as depth of invasion. Context remains connected to the case so that pathologists can move efficiently through tasks like lymph node counts. Image analysis is built directly into the viewer, allowing regions of interest to be refined and results to update in real time with supporting evidence available for expert verification. Reportable findings are assembled in the same pass for pathologist confirmation. The result is greater focus and speed with less manual effort.
- Automate laboratory operations. Operations teams keep pace with growing case volumes while maintaining turnaround times. AI helps balance workloads, recommend stain panels and ancillary studies, and surface operational bottlenecks before they impact performance. Purpose-built worklists and dashboards provide visibility across sites and scanners, helping teams keep cases moving without switching tools or chasing down updates. Automated storage tiering matches placement to how each site uses its data, reducing long-term storage costs by more than half while preserving secure, governed access to the cases that power re-review, future AI validation, and biopharmaceutical collaborations.
- Drive business growth. Laboratories can expand into high-margin specialty testing and grow their role in precision medicine. Molecular workflows inside Concentriq reduce manual handoffs and optimise tissue at every step with digital macro dissection and native AI tumour detection, making advanced molecular testing easier to scale with high-quality data. Through the network Concentriq enables, laboratories can collaborate with biopharmaceutical companies on real-world data programs, clinical trials, and companion diagnostic development, among other initiatives.
"As one of the first laboratories to go digital, we've seen firsthand how technology reshapes pathology, and Concentriq has enabled that journey," said Dr Derek Welch, President and Chief Medical Officer of PathGroup. "Fifth Generation applies AI in an entirely new way, removing the invisible labour that surrounds case review so pathologists can spend more time on the decisions that only they can make."
Concentriq supports the precision medicine lifecycle by helping biopharmaceutical companies discover biomarkers and develop therapies while creating a network for matching patients to the right treatments.
Precision medicine teams can bring biomarkers and companion diagnostics into routine clinical use. Concentriq supports teams building and validating assays with access to multimodal real-world data that enables biomarker validation and the production of evidence required for regulatory approval. With millions of patient cases diagnosed annually across academic, reference, and health system laboratories, Concentriq also helps carry validated diagnostics from approval to broad clinical adoption at scale.
The Fifth Generation of Concentriq is available now to current customers through Proscia's early access programme. Initial deployments begin June 2026 with select laboratories and biopharmaceutical companies, and broader availability follows later this year. Organisations not yet on Concentriq can request priority access by contacting Proscia.
Learn more About the Fifth Generation of Concentriq by clicking here to register to join Proscia’s live product walkthrough and demonstration webinar on 28 July 28, at 12pm ET / 5pm BST.